Condition: Triple Negative Breast Cancer · Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.
The goal of this clinical trial is to investigate if treatment with bulumtatug fuvedotin is effective in triple-negative breast cancer patients who have previously received treatment with an antibody-drug conjugates.
This description comes directly from the study's public registry record.
Fan Gao · +8615122736763 · fan.gao@mabwell.com
Wenhui Zhang, MD · wenhui.zhang@mabwell.com
Always discuss trial participation with your own doctor first.
| City of Hope | Duarte, California, United States | Recruiting |
| UCSD Moores Cancer Center | La Jolla, California, United States | Recruiting |
| Anschutz Medical Center | Aurora, Colorado, United States | Recruiting |
| UChicago Medicine Comprehensive Cancer Center | Chicago, Illinois, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06908928